1. Home
  2. DNOW vs ADPT Comparison

DNOW vs ADPT Comparison

Compare DNOW & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NOW Inc.

DNOW

NOW Inc.

HOLD

Current Price

$11.39

Market Cap

2.7B

Sector

Industrials

ML Signal

HOLD

Logo Adaptive Biotechnologies Corporation

ADPT

Adaptive Biotechnologies Corporation

HOLD

Current Price

$13.17

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DNOW
ADPT
Founded
1862
2009
Country
United States
United States
Employees
N/A
624
Industry
Metal Fabrications
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.0B
IPO Year
2014
2019

Fundamental Metrics

Financial Performance
Metric
DNOW
ADPT
Price
$11.39
$13.17
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
9
Target Price
$16.67
$17.78
AVG Volume (30 Days)
3.6M
1.7M
Earning Date
05-25-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
63.89
EPS
N/A
N/A
Revenue
$2,648,000,000.00
$276,976,000.00
Revenue This Year
$70.53
$3.98
Revenue Next Year
$8.01
$22.72
P/E Ratio
N/A
N/A
Revenue Growth
25.68
54.77
52 Week Low
$11.10
$6.68
52 Week High
$17.48
$20.76

Technical Indicators

Market Signals
Indicator
DNOW
ADPT
Relative Strength Index (RSI) 31.75 30.42
Support Level $11.34 $12.32
Resistance Level $16.33 $13.45
Average True Range (ATR) 0.50 0.82
MACD -0.09 -0.29
Stochastic Oscillator 20.97 20.71

Price Performance

Historical Comparison
DNOW
ADPT

About DNOW NOW Inc.

Dnow Inc is a company engaged in world-wide supplying of energy and industrial products and packaged, engineered process and production equipment with a legacy of over one sixty years. It offers a broad set of supply chain solutions combined with a suite of digital solutions branded as DigitalNOW that provide customers world-class technology for digital commerce, data and information management. Its locations provide products and solutions to exploration and production companies, midstream transmission and storage companies, refineries, chemical companies, utilities, mining, municipal water, manufacturers, engineering and construction companies. The Company has three reportable segments being United States, Canada and International.

About ADPT Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Share on Social Networks: